Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

RTCure

Financiado

Cerrado

Rheuma Tolerance for Cure

In line with IMI2 goals for improved therapies and precision medicine, the aim of this proposal is to prevent and treat RA or its progression by inhibiting maturation/expansion of pathogenic autoimmune responses through immune tol... ver más

31/08/2023

14M€

Presupuesto del proyecto: 14M€

Líder del proyecto

KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 21 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-08-31

IMI2-2016-09-02: DEVELOPMENT OF IMMUNE TOLERANCE THE...

I+D

Cerrada hace 8 años

0% 44% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

21 Participantes

1.29M€ | Lider

VOEDSELBANK LIMBURG

169.34K€ | Participante

DRFZ

453.45K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

GAPAID Genes And Proteins for AutoImmunity Diagnostics 2M€ Cerrado

RYC2021-033828-I Identification of novel therapeutic targets and biomarkers o... 236K€ Cerrado

PRACTICE Prevent Rheumatoid Arthritis in Practice 156K€ Cerrado

ARCAID Amsterdam Rheumatology Center for AutoImmune Diseases 4M€ Cerrado

a-Doc Intelligent Personalised Disease Monitoring Device: a-Doc 75K€ Cerrado

IACOBUS Diagnosis and Monitoring of Inflammatory and Arthritic disea... 4M€ Cerrado

Duración del proyecto: 72 meses Fecha Inicio: 2017-08-25
Fecha Fin: 2023-08-31

Líder del proyecto

KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 14M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto In line with IMI2 goals for improved therapies and precision medicine, the aim of this proposal is to prevent and treat RA or its progression by inhibiting maturation/expansion of pathogenic autoimmune responses through immune tolerising treatments of subjects not only in early stages of joint inflammation (undifferentiated arthritis and early RA) but also in even earlier defined stages i.e. before onset of joint inflammation, when patients have arthralgia and/or bone loss, or sub-clinical stages of joint inflammation. Today, no drugs are approved for these early phases of RA development, where symptoms such as pain and fatigue cause major loss of life quality and where successful interference would prevent onset of disease. Thus, an important part of our work will be to achieve a better understanding of this as yet unexplored phase of disease. In the proposed project we will develop and validate new methods to identify individuals at high risk for RA, tools to monitor disease progress and expand and further develop cohorts suitable for these purposes. Furthermore we will validate and standardise methods to monitor immune tolerance to be used in clinical trials for tolerising therapies for RA. The aim is thus to interfere with the specific immune reactions that contribute to RA symptoms in such a way that a specific and long-lasting therapeutic effect (ultimately a cure) is accomplished for a major proportion of RA patients and prevention of diseases is accomplished in individuals at high risk for RA. Investigator-initiated as well as company-sponsored clinical trials in well stratified patient groups will be performed in collaboration with SMEs and/or contributing pharma companies and their immune effects studied using the same panel of biomarkers allowing for standardisation across protocols. Our ambition is also to disseminate our experiences from RA to other rheumatic and other immune-mediated diseases.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores